Leerink Partners analyst Lili (Aurélie) Nsongo has maintained their bullish stance on RFM stock, giving a Buy rating on March 14.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lili (Aurélie) Nsongo has given her Buy rating due to a combination of factors that highlight Sensorion SAS’s potential for growth. The company is actively progressing with its pipeline, particularly with the Ph1/2 Audiogene study of SENS-501 for OTOF-mediated hearing loss, which is expected to provide significant data by mid-2025. This timeline aligns with strategic updates from competitors, positioning Sensorion to potentially differentiate itself in the market.
Lili also notes the company’s financial health, with FY24 revenue aligning closely with expectations and a strong cash position of €77 million. This financial stability supports ongoing research and development efforts, including the SNES-401 trial for cis-platin-induced ototoxicity, which is anticipated to yield results by the end of 2025. These elements collectively underscore Sensorion’s promising outlook, justifying the Buy recommendation.
According to TipRanks, (Aurélie) Nsongo is ranked #8856 out of 9384 analysts.
In another report released on March 14, Stifel Nicolaus also maintained a Buy rating on the stock with a €1.50 price target.
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue